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Cardio pulmonary Resuscitation and Emergency Cardiovascular Care
ABSTRACT: This 2018 American Heart Association focused update 
on pediatric advanced life support guidelines for cardiopulmonary 
resuscitation and emergency cardiovascular care follows the 2018 
evidence review performed by the Pediatric Task Force of the 
International Liaison Committee on Resuscitation. It aligns with the 
International Liaison Committee on Resuscitation’s continuous evidence 
review process, and updates are published when the group completes a 
literature review based on new published evidence. This update provides 
the evidence review and treatment recommendation for antiarrhythmic 
drug therapy in pediatric shock-refractory ventricular fibrillation/
pulseless ventricular tachycardia cardiac arrest. As was the case in the 
pediatric advanced life support section of the “2015 American Heart 
Association Guidelines Update for Cardiopulmonary Resuscitation and 
Emergency Cardiovascular Care,” only 1 pediatric study was identified. 
This study reported a statistically significant improvement in return of 
spontaneous circulation when lidocaine administration was compared 
with amiodarone for pediatric ventricular fibrillation/pulseless ventricular 
tachycardia cardiac arrest. However, no difference in survival to hospital 
discharge was observed among patients who received amiodarone, 
lidocaine, or no antiarrhythmic medication. The writing group reaffirmed 
the 2015 pediatric advanced life support guideline recommendation 
that either lidocaine or amiodarone may be used to treat pediatric 
patients with shock-refractory ventricular fibrillation or pulseless 
ventricular tachycardia.
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This 2018 American Heart Association (AHA) focused update on the pediatric advanced life support (PALS) guidelines for cardiopulmonary 
resuscitation (CPR) and emergency cardiovascular care 
(ECC) is based on the systematic review of antiarrhyth-
mic drugs for cardiac arrest and the resulting “2018 
International Consensus on Cardiopulmonary Resus-
citation and Emergency Cardiovascular Care Science 
With Treatment Recommendations” (CoSTR) from the 
Pediatric Task Force of the International Liaison Com-
mittee on Resuscitation (ILCOR). The draft pediatric 
CoSTR was posted online for public comment,1 and 
a summary containing the final wording of the CoSTR 
has been published simultaneously with this focused 
update.2
AHA guidelines for CPR and ECC are developed in 
concert with the ILCOR systematic review process. In 
2015, the ILCOR evidence evaluation process transi-
tioned to a continuous one, with systematic reviews 
performed as new published evidence warrants them 
or when the ILCOR Pediatric Task Force prioritizes a 
topic. The AHA science experts then review the evi-
dence and update the AHA’s guidelines as needed, 
typically on an annual basis. A description of the evi-
dence review process is available in the 2017 CoSTR 
summary.3
The ILCOR systematic review process uses the Grad-
ing of Recommendations Assessment, Development, 
and Evaluation methodology and its associated no-
menclature to determine the quality of evidence and 
strength of recommendations for the CoSTR. The ex-
pert writing group for this 2018 PALS guidelines focused 
update reviewed the studies and analysis of the 2018 
CoSTR summary2 and carefully considered the ILCOR 
Pediatric Task Force consensus recommendations in 
light of the structure and resources of the out-of-hos-
pital and in-hospital resuscitation systems and provid-
ers who use AHA guidelines. In addition, the writing 
group determined the Classes of Recommendation and 
Levels of Evidence according to the recommendations 
of the American College of Cardiology/AHA Task Force 
on Clinical Practice Guidelines4 (Table) by using the pro-
cess detailed in the “2015 American Heart Association 
Guidelines Update for Cardiopulmonary Resuscitation 
and Emergency Cardiovascular Care.”5
It is important to note that this 2018 PALS guidelines 
focused update reevaluates only the 
recommendations for the use of antiarrhythmic drugs 
during ventricular fibrillation (VF)/pulseless 
ventricular tachycardia (pVT) cardiac arrest. All 
other recommendations and algo-rithms published 
in “Part 12: Pediatric Advanced Life Support” in the 
2015 guidelines update6 and “Part 14: Pediatric 
Advanced Life Support” in the “2010 Ameri-can 
Heart Association Guidelines for Cardiopulmonary 
Resuscitation and Emergency Cardiovascular 
Care”7 remain the official recommendations of the 
AHA ECC 
Science Subcommittee and writing groups. The recom-
mendations contained in the “2017 American Heart 
Association Focused Update on Pediatric Basic Life 
Support and Cardiopulmonary Resuscitation Quality: 
An Update to the American Heart Association Guide-
lines for Cardiopulmonary Resuscitation and Emer-
gency Cardiovascular Care” continue to apply to CPR 
delivered to pediatric patients in cardiac arrest.8
BACKGROUND
Shock-refractory VF/pVT refers to VF or pVT that persists 
or recurs after ≥1 shocks. Two antiarrhythmic medica-
tions are currently discussed in the AHA guidelines: lido-
caine, a fast sodium channel blocker (Class IB) that acts 
in part by accelerating repolarization, and amiodarone, a 
multiple ion channel blocker (Class III) that is believed to 
act predominantly by prolonging repolarization. An an-
tiarrhythmic drug alone is unlikely to pharmacologically 
convert VF/pVT to an organized perfusing rhythm. Rather, 
the primary objective of antiarrhythmic drug therapy in 
shock-refractory VF/pVT is to facilitate successful defibril-
lation and to reduce the risk of recurrent arrhythmias. 
In concert with shock delivery, antiarrhythmic drugs can 
facilitate the restoration and maintenance of a spontane-
ous perfusing rhythm. Some antiarrhythmic drugs have 
been associated with increased rates of return of sponta-
neous circulation (ROSC) and survival to hospital admis-
sion,9,10 but none have yet been demonstrated to increase 
long-term survival or survival with good neurological out-
come. Thus, establishing vascular access to enable drug 
administration should not compromise the quality of CPR 
or delay timely defibrillation, both of which are associated 
with improved long-term survival. The optimal sequence 
of PALS interventions, including administration of antiar-
rhythmic drugs during resuscitation, and the preferred 
manner and timing of drug administration in relation to 
shock delivery are still not known.
The 2018 ILCOR Pediatric Task Force review ad-
dressed the use of antiarrhythmic drugs during pediat-
ric cardiac arrest (in infants, children, and adolescents 
<18 years of age) with a shockable rhythm in any set-
ting (in hospital and out of hospital), during CPR or im-
mediately after ROSC. This review was triggered by the 
publication of 2 adult studies examining the use of anti-
arrhythmic medications in adult cardiac arrest.11,12 How-
ever, unlike previous ILCOR reviews and several earlier 
AHA PALS guidelines, the ILCOR Pediatric Task Force 
review and this 2018 PALS guidelines focused update 
are based only on pediatric studies and did not consider 
evidence extrapolated from adult studies. The writing 
group agreed that pediatric patients with VF/pVT car-
diac arrest differ substantially from adult patients in 
ways that could influence presentation, treatment, and 
response to antiarrhythmic drugs. We did not address 
the use of antiarrhythmic medications after ROSC.
USE OF ANTIARRHYTHMIC DRUGS 
DURING RESUSCITATION FROM 
PEDIATRIC VF/pVT CARDIAC ARREST
2018 Evidence Summary
Amiodarone and Lidocaine
Only 1 pediatric study was identified in the 2018 ILCOR 
systematic review of the literature.13 This same pediatric 
study was included in the 2015 guidelines update but 
was reviewed to determine whether any modification 
of AHA guidelines was warranted. The observational 
study is derived from the AHA Get With The Guidelines–
Resuscitation registry. It evaluated a cohort of children 
enrolled from 2000 to 2008 who had an in-hospital car-
diac arrest requiring CPR for at least 2 minutes, with a 
rhythm of VF/pVT at any time during the cardiac arrest.13 
Of the 9280 eligible patients with cardiac arrest, 1099 
Table. ACC/AHA Recommendation System: Applying Class of Recommendation and Level of Evidence to Clinical Strategies, Interventions, 
Treatments, or Diagnostic Testing in Patient Care* (Updated August 2015)
(12%) had VF/pVT documented at some time during the 
cardiac arrest; after those who received prearrest lido-
caine or amiodarone were excluded, 889 patients were 
available for evaluation. Patients receiving lidocaine had 
statistically higher rates of ROSC compared with patients 
receiving amiodarone or no antiarrhythmic medication. 
There was no significant difference in ROSC for patients 
receiving amiodarone compared with those receiving no 
antiarrhythmic medication. There was no difference in 
survival to hospital discharge across the 3 groups. On 
multivariate analysis, lidocaine was independently as-
sociated with ROSC (odds ratio, 2.02; 95% CI, 1.36–
3.00). Neither lidocaine nor amiodarone was found to 
have a significant independent association with survival 
to hospital discharge.
The raw data were used to calculate a relative risk 
of each outcome. There was a statistically significant 
improvement in ROSC in patients who received lido-
caine compared with amiodarone (64% versus 44%; 
P=0.004; relative risk, 1.46; 95% CI, 1.13–1.88). There 
was no statistical difference in survival to hospital dis-
charge in patients who received lidocaine compared 
with those receiving amiodarone (25% versus 17%; 
P=NS; relative risk, 1.50; 95% CI, 0.90–2.52) or when 
those who received lidocaine, amiodarone, or no anti-
arrhythmic medication were compared.
The results of this study were not reported by year of 
cardiac arrest. The study did not report adverse events, 
making it impossible to balance the risk and benefit 




1. For shock-refractory VF/pVT, either amio-
darone or lidocaine may be used (Class IIb;
Level of Evidence C-LD). This is unchanged
from the 2015 recommendation.6
The Pediatric Cardiac Arrest Algorithm—2018 
Update (Figure) is unchanged in the depiction of se-
quences and therapies from the version published in 
2015.6 To clarify the use of antiarrhythmic medica-
tions for shock-refractory VF/pVT, under Drug Therapy 
in the box on the right, the doses of amiodarone and 
lidocaine are clearly separated with the word “or.” 
The writing group also took the opportunity to review 
the complete text of the algorithm and to eliminate 
minor wording differences between the adult and 
pediatric cardiac arrest algorithms. Under Asystole/
PEA (pulseless electrical activity), in Box 10, the writ-
ing group added the word “capnography” to the last 
bullet after “Consider advanced airway” and made 
minor edits to Box 12, eliminating the bulleted phrase 
“Organized rhythm→check pulse.” In the CPR Qual-
 
ity box on the right, in the fourth bullet, the word 
“rotate” was changed to “change.” These changes 
will make the wording identical to that in the boxes 
located in the same position in the Adult Cardiac Arrest 
Algorithm—2018 Update. All other parts of the Pedi-
atric Cardiac Arrest Algorithm are unchanged.
Discussion
Past ILCOR pediatric evidence reviews, CoSTRs, and 
AHA PALS guidelines on the topic of antiarrhythmic 
therapy in pediatric cardiac arrest have incorporated 
data extrapolated from adult studies. For this update, 
the consensus of the ILCOR Pediatric Task Force was 
to consider only pediatric studies because the experts 
agreed that the pediatric cardiac arrest population dif-
fers significantly from the adult cardiac arrest popula-
tion. The most recent adult studies examining the ef-
fect of antiarrhythmic medication for shock-refractory 
VF/pVT had an average patient age of >60 years and 
specifically excluded patients <18 years of age.11,12,14 
Pediatric cardiac arrests typically occur in patients with 
progressive respiratory failure or shock, and most are 
preceded by a period of hypoxia and hypotension, 
with a terminal rhythm of bradycardia or asystole. Ven-
tricular arrhythmias are more common in certain sub-
populations, such as children with congenital heart dis-
ease or channelopathies. However, in general, VF/pVT 
is uncommon, occurring as the first documented 
rhythm in 10% to 14% of pediatric in-hospital cardiac 
arrests13,15–18 and in 7% of pediatric out-of-hospital 
cardiac arrests.19,20 Subsequent VF/pVT (ie, VF/pVT 
that develops during resuscitation from an arrest with 
a non–VF/pVT initial arrest rhythm such as pulseless 
electrical activity or asystole) occurs in 15% of pedi-
atric in-hospital cardiac arrests.15 In the Valdes et al13 
study, subsequent VF/pVT was associated with lower 
rates of ROSC and survival to hospital discharge than 
initial VF/pVT was; this outcome is consistent with other 
pediatric16,17 and adult21 reports.
Unlike pediatric cardiopulmonary arrest, cardiac ar-
rest in adults is often secondary to a sudden ventricular 
arrhythmia. Coronary occlusion with subsequent myo-
cardial ischemia serves as a common trigger for these 
arrhythmias, typically with no preceding hypoxia or hy-
potension. The most common arrest rhythm in adult 
cardiac arrest is VF/pVT, present in up to 44% of adult 
cardiac arrests.21,22 Because it is unclear how differences 
between pediatric and adult cardiac arrest may influ-
ence the effect of antiarrhythmic therapy, the writing 
group agreed with the ILCOR Pediatric Task Force to 
analyze evidence from only pediatric cardiac arrest 
studies.
The indication for the use of amiodarone or lido-
caine in this 2018 PALS guidelines focused update is 
shock-refractory VF/pVT, defined as VF or pVT that per-
sists or recurs after the delivery of at least 1 shock. In 
the Valdes et al13 study, the mean number of shocks 
administered is 3, but the number of subjects who re-
quired >1 shock is not reported, so it is impossible to 
determine with certainty how many of the patients in 
the study had shock-refractory VF/pVT. In the absence 
of evidence to the contrary, the writing group assumed 
that enrolled patients received at least 1 shock before 
Figure. Pediatric Cardiac Arrest Algorithm—2018 Update.  
CPR indicates cardiopulmonary resuscitation; ET, endotracheal; IO, intraosseous; IV, intravenous; PEA, pulseless electrical activity; pVT, pulseless ventricular tachycar-
dia; ROSC, return of spontaneous circulation; VF, ventricular fibrillation; and VT, ventricular tachycardia.
antiarrhythmic therapy and could therefore be consid-
ered to have shock-refractory VF/pVT.
Another potential limitation of the Valdes et al13 
study is the period during which patients were en-
rolled in the study. The study included patients who 
had in-hospital cardiac arrest between 2000 and 2008, 
spanning the years during which the “2005 American 
Heart Association Guidelines for Cardiopulmonary Re-
suscitation and Emergency Cardiovascular Care” were 
introduced.23 These 2005 guidelines emphasized the 
importance of high-quality CPR, including emphasis on 
minimizing interruptions in chest compressions by us-
ing a new compression-to-ventilation ratio and a new 
defibrillation sequence (1 shock followed by immedi-
ate resumption of CPR instead of 3 “stacked” shocks). 
Because recommended resuscitation sequences and 
interventions differed substantially before and after 
the implementation of the 2005 guidelines, the Valdes 
et al study was downgraded in the ILCOR systematic 
review for indirectness (ie, many patients in the study 
were treated in a manner inconsistent with current re-
suscitation practice). This issue highlights a challenge 
of resuscitation research: As guidelines are updated, 
research protocols become outdated and comparisons 
challenging. In the future, authors are encouraged to 
provide subgroup analyses of patients enrolled in stud-
ies after major guideline changes.
for VF/pVT cardiac arrest, including administration 
of a vasopressor or antiarrhythmic medication, and 
the timing of medication administration in relation to 
shock delivery are not known. The sequence of inter-
ventions recommended in the current PALS algorithm 
should consider the individual patient and the envi-
ronment of care.
Future updates will address new research such as 
targeted temperature management after ROSC24 and 
hemodynamic monitoring to guide CPR quality25–27 to 
integrate new published evidence into resuscitation 
recommendations.
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SUMMARY
A review of the peer-reviewed publications on antiar-
rhythmic therapy in pediatric shock-refractory VF/pVT  
cardiac arrest resulted in no change in PALS guide-
line recommendations but has identified s everal 
gaps in our knowledge. As noted in the 2010 guide-
lines,7 high-quality CPR and defibrillation are the only 
therapies proven to increase survival in patients with  
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